EGFR-target therapy (cetuximab and panitumumab) and small-molecule TKIs have been reported to inhibit tumor growth and disease progression, which demonstrate the promising therapeutic option in CRC patients 6. This evidence concerns the gene EGFR and colorectal carcinoma.